公开(公告)号：US20080166347A1

公开(公告)日：2008-07-10

申请号：US11827306

申请日：2007-07-11

Applicant: Jan G.J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard ,  Jorgen Petersen

Inventor： Jan G.J. van de Winkel ,  Marcus A. van Dijk ,  Janine Schuurman ,  Arnout F. Gerritsen ,  Ole Baadsgaard ,  Jorgen Petersen

IPC: A61K39/00

CPC classification number: C07K16/24 ,  A01K2217/05 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  Y10S514/885

Abstract: Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与IL-15（例如人IL-15）特异性结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换而在能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠中产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20250101102A1

公开(公告)日：2025-03-27

申请号：US18833267

申请日：2023-01-27

Applicant: GENMAB A/S

Inventor： Christopher W. L. CHIU ,  Mariana C. STIRNER ,  Minh H. DINH ,  Iliana E. SZAFER-GLUSMAN

IPC: C07K16/28 ,  A61K31/573 ,  A61K39/00 ,  A61P35/00

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).

公开(公告)号：US20250066507A1

公开(公告)日：2025-02-27

申请号：US18798557

申请日：2024-08-08

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  OyewaleV O. ABIDOYE ,  Leonardo Viana NICACIO ,  Anthony CAO ,  Shyra GARDAI

IPC: C07K16/36 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

公开(公告)号：US20250002610A1

公开(公告)日：2025-01-02

申请号：US18755457

申请日：2024-06-26

Applicant: Genmab A/S

Inventor： Bart E.C.G. De Goeij ,  Ilse Jongerius ,  Grietje Andringa ,  Madelon Paauwe ,  Theodorus Sjouuke Plantinga ,  David Satijn ,  Jamila Laoukili ,  Onno Wouter Kranenburg ,  Marije Overdijk

IPC: C07K16/46 ,  A61K39/00 ,  A61P35/04 ,  G01N33/68

Abstract: The present invention relates to a multispecific antibody comprising at least a FAPα binding region comprising a first heavy chain variable region and a first light chain variable region; and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240376221A1

公开(公告)日：2024-11-14

申请号：US18660672

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/42

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240368297A1

公开(公告)日：2024-11-07

申请号：US18633939

申请日：2024-04-12

Applicant: Genmab A/S

Inventor： Tommy R. LI ,  Craig J. THALHAUSER

IPC: C07K16/28 ,  A61K31/138 ,  A61K31/573 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides dosing regimens of bispecific antibodies targeting both CD3 and CD20 when used in the treatment of lymphoma, such as B-cell Non-Hodgkin lymphoma (B-NHL).

公开(公告)号：US12077596B2

公开(公告)日：2024-09-03

申请号：US17360438

申请日：2021-06-28

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Friederike Gieseke ,  Ugur Sahin

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  G01N33/56972 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/92

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20240262924A1

公开(公告)日：2024-08-08

申请号：US18570257

申请日：2022-06-20

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria N. JURE-KUNKEL ,  Gaurav BAJAJ ,  Craig THALHAUSER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.

公开(公告)号：US20240209117A1

公开(公告)日：2024-06-27

申请号：US18507869

申请日：2023-11-13

Applicant: GENMAB A/S

Inventor： Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Edwald T. J. VAN DER BREMER ,  Joost J. NEIJSSEN ,  Patrick VAN BERKEL ,  Bart DE GOEIJ ,  Tom VINK ,  Jan VAN DE WINKEL ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/46 ,  A61K39/00 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/40 ,  G01N33/68

CPC classification number: C07K16/468 ,  C07K16/1063 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/40 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins

公开(公告)号：US11970544B2

公开(公告)日：2024-04-30

申请号：US17353087

申请日：2021-06-21

Applicant: GENMAB A/S

Inventor： David Satijn ,  Esther C. W. Breij ,  Bart E. C. G. De Goeij ,  Kristel Kemper ,  Patrick Engelberts ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Dennis Verzijl ,  Sjeng Horbach ,  Paul Parren

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K39/00

CPC classification number: C07K16/30 ,  A61P35/00 ,  C12N15/79 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/565

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.